In trading on Monday, shares of AcelRx Pharmaceuticals Inc (ACRX - Get Report) touched a new 52-week high of $5.50/share. That's a 182.05% rise, or $3.55 per share from the 52-week low of $1.95 set back on 06/12/2017. That means at today's intraday high, any investor who purchased ACRX stock any time over the past 52 weeks has an unrealized gain, including company insiders.Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, ACRX has seen 4 different instances of insiders buying over the trailing six month period.
|08/22/2017||Pamela P. Palmer||Chief Medical Officer||10,000||$2.95||$29,487.00|
|08/24/2017||Mark G. Edwards||Director||5,000||$3.02||$15,100.00|
|08/24/2017||Vincent J. Angotti||Chief Executive Officer||15,000||$3.00||$45,000.00|
|09/11/2017||Raffi Asadorian||Chief Financial Officer||7,000||$3.24||$22,705.20|